# Catheter Ablation for Channelopathies: When Is Less More?

## TL;DR

This paper reviews the use of catheter ablation as a treatment for heart rhythm disorders called channelopathies, focusing on its potential to reduce life-threatening arrhythmias and improve quality of life.

## Contribution

The paper evaluates the emerging role of catheter ablation in managing channelopathies, emphasizing the need for further research on its long-term efficacy and benefits over existing therapies.

## Key findings

- Catheter ablation shows promise in treating Brugada syndrome but requires more study for other channelopathies.
- Advances in imaging and mapping have improved understanding of arrhythmia mechanisms in channelopathies.
- Current therapies for channelopathies have significant drawbacks, prompting interest in catheter ablation as an alternative.

## Abstract

Ventricular fibrillation (VF) is a common cause of sudden cardiac death in patients with channelopathies, particularly in the young population. Although pharmacological treatment, cardiac sympathectomy, and implantable cardioverter defibrillators (ICD) have been the mainstay in the management of VF in patients with channelopathies, they are associated with significant adverse effects and complications, leading to poor quality of life. Given these drawbacks, catheter ablation has been proposed as a therapeutic option for patients with channelopathies. Advances in imaging techniques and modern mapping technologies have enabled increased precision in identifying arrhythmia triggers and substrate modification. This has aided our understanding of the underlying pathophysiology of ventricular arrhythmias in channelopathies, highlighting the roles of the Purkinje network and the epicardial right ventricular outflow tract in arrhythmogenesis. This review explores the role of catheter ablation in managing the most common channelopathies (Brugada syndrome, congenital long QT syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia). While the initial results for ablation in Brugada syndrome are promising, the long-term efficacy and durability of ablation in different channelopathies require further investigation. Given the genetic and phenotypic heterogeneity of channelopathies, future studies are needed to show whether catheter ablation in patients with channelopathies is associated with a reduction in VF, and psychological distress stemming from recurrent ICD shocks, particularly relative to other available therapeutic options (e.g., quinidine in high-risk Brugada patients).